Publications by authors named "Saadet Sim"

Claim this Profile
R
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.
Gökhan Şahin, Esmanur Kaplan Tüzün, Halil G Güzel, Murad Guliyev, Ahmet K Dişli, Saadet Sim

Int J Cancer· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).
Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek

Clin Transl Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium.
Elif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, Saadet Sim, Hilal Karakaş

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.
Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Saadet Sim

BMC Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.
Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim

Immunotherapy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium.
Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek

Cancer Commun (Lond)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.
Musa Barış Aykan, Hatice Bölek, Emre Yekedüz, Elif Sertesen, Deniz Tural, Saadet Sim

Ther Adv Med Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Hatice Bölek, Elif Sertesen, Omer Faruk Kuzu, Deniz Tural, Saadet Sim

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicians' knowledge about ionizing radiation and radiological imaging techniques: a cross-sectional survey.
Aylin Yucel, Cansu Alyesil, Saadet Sim

Acta Radiol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis